Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)

National Institutes of Health · HHS

CFDA Numbers

93.866

Award Ceiling

—

Award Floor

—

Expected Awards

—

Close Date

Oct 5, 2026

Section I

How to Apply

View on grants_gov ↗

Program Contact

NIA-NOFO-Scientific@nih.gov
Please contact via e-mail.

Section II

Eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Eligible Applicant Types

00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25

Section III

Description

The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on Alzheimer's disease (AD) and AD-related dementias (ADRD) drug target validation and early-stage drug discovery against novel targets. This NOFO will utilize the U01 activity code. The NOFO will support rigorous preclinical AD/ADRD drug target validation and early-stage drug discovery of small molecules, biologic, and emerging therapeutic modalities. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into AD/ADRD and drug discovery are encouraged to begin to consider applying for this new NOFO.

Section IV

Key Dates

Posted: Jul 31, 2026
Closes: Oct 5, 2026